SPRB · Spruce Biosciences, Inc.
$42.28
-2.71 (-6.02%)
At close · Jul 24
Market Cap
$118.57M
Shares
2.75M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$44.99
Open$44.16
Day$42.51–45.06
52W$7.00–838.13
Avg vol 30d81K
Short int416K · 15.1% float · 6.1d
Short vol35%
Last earningsNov 12, 2024
DataOct 2020–Jul 2026
Filing10-Q · May 13
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 13, 2026
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 18.6 · elevated
Equity put/call 0.79
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−41%
below
Price vs 50-day avg
−11%
below
RSI (14)
39
neutral
MACD trend
Negative
52-week position
5%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−13%
trailing
6-month return
−44%
trailing
YTD return
−48%
this year
Relative strength
−50%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $50 › 200d $76 — 200d above 50d
Institutional flow
Accumulating
4 of 32 funds reported for Jun 30 · net +872 sh shares · +3 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
15.11% of float · ▲ +15.7% MoM · 6.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
32 holders — 13F breadth
Squeeze score
73
high risk · 0–100
Fundamentals
Revenue growth
−100%
Y/Y
EPS growth
+47%
Y/Y
Free cash flow
$-33.3M
Balance sheet
$48.9M
net cash
Quant / Vol
risk profile
Volatility
1390%
annualized · 1-yr
Max drawdown
−99%
past year
ATR
6.8%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−41%
Bearish
Price vs 50-day avg
−11%
Bearish
RSI (14)
39
Neutral
MACD trend
Negative
Bearish
52-week position
5%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $50 › 200d $76 — 200d above 50d
Institutional flow
Accumulating
4 of 32 funds reported for Jun 30 · net +872 sh shares · +3 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
15.11% of float · ▲ +15.7% MoM · 6.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
32 holders — 13F breadth
Price context
position in its 52-week range
52-wk low $7
Now $45 · 5%
52-wk high $838
vs 200-day avg -41%
vs 50-day avg -11%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
SPRB
this stock
Spruce Biosciences, Inc.
|
$118.57M | -48.4% | -100.0% | — | 15.1% |
|
ONC
BeOne Medicines Ltd.
|
$471.01B | +7.6% | +22179.2% | 958.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$121.16B | +4.4% | +46.2% | 28.3 | 2.0% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$68.78B | -15.4% | +20.8% | 16.0 | 3.3% |
|
ARGX
Argenx SE
|
$57.44B | +9.9% | — | — | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| SPRB | +1.6% | -13.3% | -43.7% | -16.7% | -48.4% |
| SPY | -1.7% | +0.7% | +6.4% | -1.2% | +8.3% |
| vs SPY | +3.3% | -13.9% | -50.0% | -15.5% | -56.6% |